FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992848513> ?p ?o ?g. }

• W1992848513 endingPage "612" @default.
• W1992848513 startingPage "601" @default.
• W1992848513 abstract "OBJECTIVE Ferumoxytol, an iron oxide nanoparticle that targets phagocytic cells, can be used in magnetic resonance imaging of malignant brain tumors and can be administered as a bolus, allowing dynamic imaging. Our objectives were to determine the optimum time of delayed contrast enhancement of ferumoxytol, and to compare ferumoxytol and gadolinium contrast agents for magnetic resonance angiography and perfusion. METHODS Twelve patients with malignant brain tumors underwent serial magnetic resonance imaging multiple times up to 72 hours after ferumoxytol injection at both 1.5 and 3-T. The enhancement time course was determined for ferumoxytol and compared with a baseline gadolinium scan. Perfusion, time-of-flight and dynamic magnetic resonance angiography and T1-weighted scans were compared for the two agents. RESULTS The lesions were detectable at all field strengths, even with an intraoperative 0.15-T magnet. Maximal ferumoxytol enhancement intensity was at 24 to 28 hours after administration, and the enhancing volume subsequently expanded with time into a non-gadolinium-enhancing, high T2-weighted signal region of tumor-infiltrated brain. Dynamic studies were assessed with both agents, indicating early vascular leak with gadolinium but not with ferumoxytol. CONCLUSION Our most important finding was that gadolinium leaks out of blood vessels early after injection, whereas ferumoxytol stays intravascular in the “early” phase, thereby increasing the accuracy of tumor perfusion assessment. As a magnetic resonance imaging contrast agent, ferumoxytol visualizes brain tumors at all field strengths evaluated, with delayed enhancement peaking at 24 to 28 hours after administration." @default.
• W1992848513 created "2016-06-24" @default.
• W1992848513 creator A5002536570 @default.
• W1992848513 creator A5014536479 @default.
• W1992848513 creator A5025342160 @default.
• W1992848513 creator A5027993667 @default.
• W1992848513 creator A5028995402 @default.
• W1992848513 creator A5031187490 @default.
• W1992848513 creator A5036618990 @default.
• W1992848513 creator A5056428329 @default.
• W1992848513 creator A5062971835 @default.
• W1992848513 creator A5073708216 @default.
• W1992848513 creator A5078607888 @default.
• W1992848513 date "2007-04-01" @default.
• W1992848513 modified "2023-10-11" @default.
• W1992848513 title "THE POTENTIAL OF FERUMOXYTOL NANOPARTICLE MAGNETIC RESONANCE IMAGING, PERFUSION, AND ANGIOGRAPHY IN CENTRAL NERVOUS SYSTEM MALIGNANCY" @default.
• W1992848513 cites W1972582749 @default.
• W1992848513 cites W1974862189 @default.
• W1992848513 cites W1979234968 @default.
• W1992848513 cites W1983569280 @default.
• W1992848513 cites W2005854135 @default.
• W1992848513 cites W2006858976 @default.
• W1992848513 cites W2007191608 @default.
• W1992848513 cites W2011272082 @default.
• W1992848513 cites W2015182248 @default.
• W1992848513 cites W2022280660 @default.
• W1992848513 cites W2023759724 @default.
• W1992848513 cites W2027981703 @default.
• W1992848513 cites W2030959855 @default.
• W1992848513 cites W2034490173 @default.
• W1992848513 cites W2039457015 @default.
• W1992848513 cites W2040158959 @default.
• W1992848513 cites W2042145418 @default.
• W1992848513 cites W2051421116 @default.
• W1992848513 cites W2063999920 @default.
• W1992848513 cites W2072127166 @default.
• W1992848513 cites W2081948046 @default.
• W1992848513 cites W2083784395 @default.
• W1992848513 cites W2094062697 @default.
• W1992848513 cites W2115964253 @default.
• W1992848513 cites W2116810900 @default.
• W1992848513 cites W2123005841 @default.
• W1992848513 cites W2132527182 @default.
• W1992848513 cites W2146123518 @default.
• W1992848513 cites W2147379000 @default.
• W1992848513 cites W2162740426 @default.
• W1992848513 cites W2171158566 @default.
• W1992848513 cites W4233170666 @default.
• W1992848513 cites W4237239211 @default.
• W1992848513 cites W4245426790 @default.
• W1992848513 doi "https://doi.org/10.1227/01.neu.0000255350.71700.37" @default.
• W1992848513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17415196" @default.
• W1992848513 hasPublicationYear "2007" @default.
• W1992848513 type Work @default.
• W1992848513 sameAs 1992848513 @default.
• W1992848513 citedByCount "164" @default.
• W1992848513 countsByYear W19928485132012 @default.
• W1992848513 countsByYear W19928485132013 @default.
• W1992848513 countsByYear W19928485132014 @default.
• W1992848513 countsByYear W19928485132015 @default.
• W1992848513 countsByYear W19928485132016 @default.
• W1992848513 countsByYear W19928485132017 @default.
• W1992848513 countsByYear W19928485132018 @default.
• W1992848513 countsByYear W19928485132019 @default.
• W1992848513 countsByYear W19928485132020 @default.
• W1992848513 countsByYear W19928485132021 @default.
• W1992848513 countsByYear W19928485132022 @default.
• W1992848513 countsByYear W19928485132023 @default.
• W1992848513 crossrefType "journal-article" @default.
• W1992848513 hasAuthorship W1992848513A5002536570 @default.
• W1992848513 hasAuthorship W1992848513A5014536479 @default.
• W1992848513 hasAuthorship W1992848513A5025342160 @default.
• W1992848513 hasAuthorship W1992848513A5027993667 @default.
• W1992848513 hasAuthorship W1992848513A5028995402 @default.
• W1992848513 hasAuthorship W1992848513A5031187490 @default.
• W1992848513 hasAuthorship W1992848513A5036618990 @default.
• W1992848513 hasAuthorship W1992848513A5056428329 @default.
• W1992848513 hasAuthorship W1992848513A5062971835 @default.
• W1992848513 hasAuthorship W1992848513A5073708216 @default.
• W1992848513 hasAuthorship W1992848513A5078607888 @default.
• W1992848513 hasConcept C126838900 @default.
• W1992848513 hasConcept C143409427 @default.
• W1992848513 hasConcept C146957229 @default.
• W1992848513 hasConcept C191897082 @default.
• W1992848513 hasConcept C192562407 @default.
• W1992848513 hasConcept C2778212899 @default.
• W1992848513 hasConcept C2909801847 @default.
• W1992848513 hasConcept C2989005 @default.
• W1992848513 hasConcept C557651011 @default.
• W1992848513 hasConcept C71924100 @default.
• W1992848513 hasConceptScore W1992848513C126838900 @default.
• W1992848513 hasConceptScore W1992848513C143409427 @default.
• W1992848513 hasConceptScore W1992848513C146957229 @default.
• W1992848513 hasConceptScore W1992848513C191897082 @default.
• W1992848513 hasConceptScore W1992848513C192562407 @default.
• W1992848513 hasConceptScore W1992848513C2778212899 @default.
• W1992848513 hasConceptScore W1992848513C2909801847 @default.
• W1992848513 hasConceptScore W1992848513C2989005 @default.

• next